Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymphocyte depletion experiments demonstrated that the efficacy of CCL16/CpG/anti-IL-10R combination treatment relies upon CD8 T lymphocytes whereas CD4 T cells are dispensable. The results underlie the feasibility of echo-guided local immunotherapy of tumors located in visceral organs that are not easily accessible
|Numero di pagine||9|
|Rivista||CANCER IMMUNOLOGY, IMMUNOTHERAPY|
|Stato di pubblicazione||Published - 2013|
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Cancer Research
Tripodo, C., Mauri, G., Arioli, I., Chiodoni, C., Parenza, M., & Colombo, M. P. (2013). Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 12, 1811-1819.